Treace Medical Concepts, Inc.

NASDAQ•TMCI

CEO: Mr. John T. Treace

セクター: Healthcare

業種: Medical - Devices

上場日: 2021-04-23

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

連絡先情報

100 Palmetto Park Place, Ponte Vedra, FL, 32081, United States

904-373-5940

www.treace.com

時価総額

$87.20M

PER (TTM)

-1.5

配当利回り

52週高値

$8.87

52週安値

$1.31

52週レンジ

順位58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$62.52M+0.00%

直近4四半期の推移

EPS

-$0.15+0.00%

直近4四半期の推移

フリーCF

-$10.42M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Modest Total revenue reached $212.69M in 2025, marking a modest 1.6% increase compared to 2024 results.

Sales Expense Optimization Sales and marketing expenses decreased by $6.76M, reflecting a 4.6% reduction compared to the previous year.

Surgeon Base Expansion Active surgeon base expanded by 6% to 3,337 users performing procedures across various company systems.

New Debt Financing Secured Company secured a new $175.0M senior secured loan facility in December 2025 to support operations and growth.

リスク要因

Sustained Profitability Challenge Incurred net loss of $59.0M for 2025; achieving and sustaining profitability remains a significant challenge.

Flagship Product Dependence Revenue remains highly dependent on Lapiplasty System sales, which are experiencing slower growth due to market shifts.

Intense Market Competition Intense competition and evolving surgeon preferences for minimally invasive osteotomies negatively impact flagship Lapiplasty revenue.

Active Litigation Exposure Company faces shareholder class action and patent infringement litigation risks, potentially draining financial resources and management time.

見通し

Next-Gen Product Launch Next-generation Lapiplasty Lightning platform is slated for commercialization in 2026, aiming for faster procedures and greater accuracy.

Sales Force Strategy Focus Strategy focuses on optimizing direct sales force structure and coordination to facilitate growth and improve long-term operating leverage.

R&D Pipeline Expansion R&D efforts focus on developing complementary products that leverage existing fixation platforms to expand market position.

Direct Education Spending Cut Management plans to reduce spending on direct-to-patient outreach programs in 2026 while maintaining brand awareness efforts.

同業比較

売上高 (TTM)

EHAB

$1.06B

+2.4%

BVS

$568.09M

-0.9%

TOI

$502.73M

+27.8%

粗利益率 (最新四半期)

SMLR

91.5%

+0.1pp

DCTH

85.5%

+1.9pp

LAB

83.5%

-3.2pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
EHAB	$689.84M	-149.9	-0.8%	42.8%
SRDX	$614.51M	-34.8	-15.6%	19.2%
BVS	$576.00M	25.2	13.8%	45.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

5.9%

安定成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

25%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし